HRP20161251T1 - Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe - Google Patents
Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe Download PDFInfo
- Publication number
- HRP20161251T1 HRP20161251T1 HRP20161251TT HRP20161251T HRP20161251T1 HR P20161251 T1 HRP20161251 T1 HR P20161251T1 HR P20161251T T HRP20161251T T HR P20161251TT HR P20161251 T HRP20161251 T HR P20161251T HR P20161251 T1 HRP20161251 T1 HR P20161251T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- platform
- seq
- drug
- specific target
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 2
- 102000002090 Fibronectin type III Human genes 0.000 title 1
- 108050009401 Fibronectin type III Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007919 intrasynovial administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 239000000409 cytokine receptor agonist Substances 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- -1 hormonal drug Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229940124622 immune-modulator drug Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 229940126702 topical medication Drugs 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Claims (14)
1. Izolirana proteinska platforma koja sadrži sekvencu amino kiseline koja ima najmanje 75% identičnosti sa SEQ ID BR: 16, koja ima 7 lanaca i 6 petlji između lanaca, i koja sadrži sekvencu amino kiseline od SEQ ID BR: 16, ali u kojoj je jedna ili više petlji izmijenjeno da bi se vezale za metu, dok lanci održavaju svoje sekvence kao dijelove kostura, pri čemu su petlje na ostacima 13-16, 22-28, 38-43, 51-54, 60- 64 i 75 do 81 od SEQ ID BR: 16, i sposobne su za vezivanje na stanične proteine i/ili molekule nukleinske kiseline.
2. Izolirana proteinska platforma prema patentnom zahtjevu 1, pri čemu su, regije petlje na ili oko 22-28 ostataka, 51-54 i 75-81 od SEQ ID BR: 16 promijenjene za specifičnost vezivanja i afinitet.
3. Izolirana proteinska platforma prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu se izolirana proteinska platforma veže na ciljni protein sa KD jednakom ili manjom od oko 10-7 M, kao što je 0,1-9,9 X 10-8, 10-9, 10 -10, 10-11, 10-12, 10-13, 10-14 ili 10-15 M, kao što je određeno površinskom plazmon rezonancom "Kinexa" metode.
4. Postupak konstruiranja biblioteke proteinskih platformi prema bilo kojem od patentnih zahtjeva 1-3, koji sadrži korake pružanje polipeptida koji ima amino kiselinsku sekvencu od SEQ ID BR: 16; i uvođenje različitosti u kopijama polipeptida koji imaju aminokiselinsku sekvencu SEQ ID BR: 16 da se formira biblioteka proteinskih platformi, pri čemu korak uvođenja različitosti sadrži mutiranje najmanje jedne regije petlje izabrane iz grupe koja se sastoji od ostataka na oko položaja 13-16, 22-28, 38-43, 51-54, 60-64 i 75-81 iz SEQ ID BR: 16.
5. Biblioteka proizvedena postupkom prema patentnom zahtjevu 4.
6. Postupak dobivanja proteinske platforme koja se veže za određenu metu sa prethodno definiranim afinitetom vezivanja, koji sadrži dovođenje u dodir biblioteke iz patentnog zahtjeva 5 sa specifičnom metom i izoliranje proteinske platforme koja se veže za određenu metu sa prethodno definiranim afinitetom.
7. Postupak prema patentnom zahtjevu 6, pri čemu korak izoliranja sadrži izoliranje platformskih molekula koje se vežu na određenu metu i testiranje izoliranih platformskih molekula za afinitet vezivanja na određenu metu, pri čemu, opcionalno:
(i) korak izoliranja sadrži pomicanje biblioteke sa određenom metom, identificiranje platformskih molekula koje se vezuju na određenu metu i izoliranje vezujućih platformskih molekula; ili
(ii) afinitet je manji od ili jednak oko 10-7M.
8. Izolirana molekula nukleinske kiseline koja kodira proteinsku platformu prema bilo kojem od patentnih zahtjeva od 1-3.
9. Izolirana molekula nukleinske kiseline iz patentnog zahtjeva 8, koja sadrži nukleotidnu sekvencu danu u SEQ ID BR: 17.
10. Izolirani vektor nukleinske kiseline koji sadrži izoliranu molekulu nukleinske kiseline prema patentnom zahtjevu 8.
11. Prokariotska ili eukariotska domaćinska stanica koja sadrži izoliranu molekulu nukleinske kiseline prema patentnom zahtjevu 8, pri čemu je navedena domaćinska stanica opcionalno barem jedna izabrana od E. koli BL21Star (DE3), druga ćelija E. koli, kvasca, COS-1, COS- 7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, mijeloma ili stanica limfoma, ili bilo koji njihovi derivati, besmrtne ili transformirane stanice.
12. Sastav koji sadrži proteinsku platformu prema bilo kojem od patentnih zahtjeva 1-3 i najmanje jedan farmaceutski prihvatljiv nosač ili diluens, opcionalno dalje sadržavajući najmanje jedan spoj ili polipeptid odabran od detektabilnih oznaka ili reportera, TNF antagonista, antiinfektivnog lijeka, lijeka kardiovaskularnog (CV) sustava, lijeka centralnog živčanog sustava (CNS), lijeka autonomnog živčanog sustava (ANS), lijeka respiratornog trakta, lijeka gastrointestinalnog (GI) trakta, hormonskog lijeka, lijeka za ravnotežu tekućina ili elektrolita, hematološkog lijeka, antineoplastičnog, imunomodulacijskog lijeka, oftalmološkog, otičkog ili nazalnog lijeka, topičkog lijeka, nutricionog lijeka, citokina, ili antagonista citokina.
13. Medicinski uređaj, koji sadrži proteinsku platformu prema bilo kojem od patentnih zahtjeva 1-3, pri čemu je navedeni uređaj pogodan za dovođenje u dodir ili primjenu navedene proteinske platforme najmanje jednim od slijedećih načina, izabrano od, parenteralnog, supkutanog, intramuskularnog, intravenoznog, intraartikularnog, intrabronhojalng, intraabdominalnog, intrakapsularnog, intrakartilaginoznog, intrakavitarnog, intracelularnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastičnog, intrahepatičnog, intramiokardialnog, intraostealnog, intrapelvičnog, intraperikardijalnog, intraperitonealnog, intrapleuralnog, intraprostatičnog, intrapulmonalnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasinovijalnog, intratorakalnog, intrauterinog, intravezikalnog, intralezionalnog, bolusnog, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog i transdermalnog.
14. Predmet proizvodnje za ljudsku, farmaceutsku ili dijagnostičku upotrebu, koji sadrži materijal za pakiranje i posudu koja sadrži otopinu ili liofilizirani oblik proteinske platforme prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je opcionalno navedena posuda komponenta parenteralnog, subkutanog, intramuskularnog, intravenoznog, intraartikularnog, intrabronhialnog, intraabdominalnog, intrakapsularnog, intrakartilaginoznog, intrakavitalnog, intracelularnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastičnog, intrahepatičnog, intramiokardialnog, intraostealnog, intrapelvičnog, intraperikardijalnog, intraperitonealnog, intrapleuralnog, intraprostatičnog, intrapulmonarnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasinovijalnog, intratorakalnog, intrauterinog, intravezikalnog, intralezionalnog, bolusnog, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog, ili transdermalnog uređaja za isporuku ili sustava.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11012008P | 2008-10-31 | 2008-10-31 | |
PCT/US2009/062200 WO2010051274A2 (en) | 2008-10-31 | 2009-10-27 | Fibronectin type iii domain based scaffold compositions, methods and uses |
EP09824067.4A EP2356269B1 (en) | 2008-10-31 | 2009-10-27 | Fibronectin type iii domain based scaffold compositions, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161251T1 true HRP20161251T1 (hr) | 2016-11-18 |
Family
ID=42129528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161251TT HRP20161251T1 (hr) | 2008-10-31 | 2016-09-29 | Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe |
Country Status (23)
Country | Link |
---|---|
US (6) | US8278419B2 (hr) |
EP (2) | EP2356269B1 (hr) |
JP (3) | JP5848607B2 (hr) |
KR (1) | KR101781907B1 (hr) |
CN (1) | CN102307896B (hr) |
AU (3) | AU2009308935B2 (hr) |
BR (1) | BRPI0919881B1 (hr) |
CA (2) | CA2741834C (hr) |
CY (1) | CY1118120T1 (hr) |
DK (1) | DK2356269T3 (hr) |
EA (1) | EA028304B1 (hr) |
ES (2) | ES2595504T3 (hr) |
HR (1) | HRP20161251T1 (hr) |
HU (1) | HUE030471T2 (hr) |
IL (4) | IL212531A (hr) |
LT (1) | LT2356269T (hr) |
MX (1) | MX2011004550A (hr) |
PL (1) | PL2356269T3 (hr) |
PT (1) | PT2356269T (hr) |
RS (1) | RS55218B1 (hr) |
SI (1) | SI2356269T1 (hr) |
SM (1) | SMT201600312B (hr) |
WO (1) | WO2010051274A2 (hr) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1946417A (zh) | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
EP3156415A1 (en) | 2006-11-22 | 2017-04-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
WO2009058379A2 (en) | 2007-10-31 | 2009-05-07 | Medimmune, Llc | Protein scaffolds |
CN102007145A (zh) | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
JP2011520961A (ja) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | 多価フィブロネクチンをベースとする足場ドメインタンパク質 |
AU2009308935B2 (en) | 2008-10-31 | 2015-02-26 | Janssen Biotech, Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
EP2396011B1 (en) * | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
CA2795325A1 (en) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
EP3569256B1 (en) * | 2010-04-30 | 2022-06-15 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
AU2015271900B2 (en) * | 2010-04-30 | 2017-02-02 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
CN103180339B (zh) | 2010-05-26 | 2016-04-27 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
US9096984B2 (en) | 2010-12-07 | 2015-08-04 | The Trustees Of Columbia University In The City Of New York | Network material devices, methods, and systems |
WO2012103347A1 (en) * | 2011-01-26 | 2012-08-02 | Whitson Stanley William | Hydrogel bioscaffold and coating for bone and tooth repair |
PT2697257T (pt) | 2011-04-13 | 2016-12-28 | Bristol Myers Squibb Co | Proteínas de fusão fc compreendendo novos ligantes ou arranjos |
EP2709669A1 (en) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
ES2848531T3 (es) | 2011-05-17 | 2021-08-10 | Bristol Myers Squibb Co | Métodos mejorados para la selección de proteínas de unión |
BR112014007469B1 (pt) | 2011-09-27 | 2022-06-14 | Janssen Biotech, Inc | Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína |
RU2019133467A (ru) | 2011-10-11 | 2020-07-06 | МЕДИММЬЮН, ЭлЭлСи | Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения |
JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
EP2855509B1 (en) * | 2012-05-25 | 2018-05-02 | Janssen Biotech, Inc. | Non-natural consensus albumin binding domains |
CN108409856B (zh) | 2012-09-13 | 2022-03-04 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
SI2922872T1 (sl) | 2012-11-21 | 2019-01-31 | Janssen Biotech, Inc., | Bispecifična protitelesa EGFR/C-MET |
US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
EP3406629B1 (en) | 2013-02-06 | 2020-06-24 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
EP3299378B1 (en) | 2013-02-12 | 2019-07-31 | Bristol-Myers Squibb Company | High ph protein refolding methods |
EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
EP2961435B1 (en) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
AU2014334627B2 (en) | 2013-10-14 | 2019-07-25 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
KR20160097294A (ko) | 2013-12-09 | 2016-08-17 | 뉴욕 유니버시티 | 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법 |
KR20220162886A (ko) | 2014-03-20 | 2022-12-08 | 브리스톨-마이어스 스큅 컴퍼니 | 혈청 알부민-결합 피브로넥틴 유형 iii 도메인 |
AU2015231210B2 (en) * | 2014-03-20 | 2019-09-12 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
KR102632830B1 (ko) | 2014-09-03 | 2024-02-02 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
US9381256B2 (en) | 2014-09-03 | 2016-07-05 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
US10564148B2 (en) | 2014-09-24 | 2020-02-18 | Triad National Security, Llc | Multi-organ media compositions and methods of their use |
US11229713B2 (en) | 2014-11-25 | 2022-01-25 | Bristol-Myers Squibb Company | Methods and compositions for 18F-radiolabeling of biologics |
EP3268389B1 (en) | 2015-03-12 | 2020-09-30 | Medimmune, LLC | Method of purifying albumin-fusion proteins |
KR20170138558A (ko) | 2015-04-24 | 2017-12-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | Hiv 융합을 표적으로 하는 폴리펩티드 |
EA201792441A2 (ru) | 2015-05-06 | 2018-06-29 | Янссен Байотек, Инк. | Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном |
WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
DK3337824T3 (da) | 2015-08-17 | 2020-08-24 | Janssen Pharmaceutica Nv | Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf |
US11124791B2 (en) | 2015-09-14 | 2021-09-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Generating recombinant affinity reagents with arrayed targets |
JP6893504B2 (ja) | 2015-09-23 | 2021-06-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプiiiドメイン |
MA43164A (fr) | 2015-11-02 | 2018-09-12 | Janssen Pharmaceutica Nv | Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations |
WO2017188215A1 (ja) * | 2016-04-27 | 2017-11-02 | 国立大学法人大阪大学 | 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤 |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
MA45186A (fr) * | 2016-06-03 | 2019-04-10 | Janssen Biotech Inc | Domaines de fibronectine de type iii se liant à l'albumine sérique |
US10662235B2 (en) | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
JP7088932B2 (ja) | 2016-09-14 | 2022-06-21 | ヤンセン バイオテツク,インコーポレーテツド | Bcma特異的フィブロネクチンiii型ドメインを有するキメラ抗原受容体、及びその使用 |
US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
WO2018111978A1 (en) * | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
WO2018111973A1 (en) * | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
TW202320794A (zh) | 2017-02-28 | 2023-06-01 | 美商伊繆諾金公司 | 具有自分解肽連接子之類美登素衍生物及其結合物 |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
MA49652A (fr) | 2017-07-17 | 2020-05-27 | Janssen Biotech Inc | Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation |
CA3074317A1 (en) * | 2017-08-25 | 2019-02-28 | Janssen Biotech, Inc. | Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them |
US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
WO2019133652A1 (en) | 2017-12-28 | 2019-07-04 | Immunogen, Inc. | Benzodiazepine derivatives |
CN110276503B (zh) * | 2018-03-14 | 2023-04-21 | 吉旗物联科技(上海)有限公司 | 一种自动识别冷链车辆任务的方法 |
KR101995774B1 (ko) * | 2018-05-08 | 2019-07-03 | 한국세라믹기술원 | 뎅기열 바이러스에 특이적으로 결합하는 피브로넥틴 edb 단백질 스캐폴드 |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
WO2020191306A1 (en) | 2019-03-21 | 2020-09-24 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
TW202102506A (zh) | 2019-03-29 | 2021-01-16 | 美商伊繆諾金公司 | 苯二氮平衍生物 |
TW202106691A (zh) | 2019-04-26 | 2021-02-16 | 美商伊繆諾金公司 | 喜樹鹼衍生物 |
AU2020313521A1 (en) | 2019-07-12 | 2022-02-17 | Janssen Pharmaceutica Nv | Binding agents and uses thereof |
CN114786682A (zh) | 2019-10-14 | 2022-07-22 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
JP2023515633A (ja) | 2020-02-28 | 2023-04-13 | ブリストル-マイヤーズ スクイブ カンパニー | 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用 |
CN115666630A (zh) * | 2020-04-08 | 2023-01-31 | 诺斯楚姆制药有限责任公司 | 使用干扰素治疗呼吸道病毒感染的组成物和方法 |
AU2021272291A1 (en) | 2020-05-11 | 2023-02-02 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
JP2023551388A (ja) | 2020-11-10 | 2023-12-08 | ニューヨーク・ユニバーシティ | マクロピノサイトーシス選択的モノボディ-薬物コンジュゲート |
JP2024507180A (ja) | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ.ベー. | Bcma、gprc5d、及びcd3を標的とする三重特異的抗体 |
JP2024506694A (ja) | 2021-02-16 | 2024-02-14 | ヤンセン バイオテツク,インコーポレーテツド | 増強されたリンカー標的化のための材料及び方法 |
US20220306738A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Antibody targeting cd22 and cd79b |
CN117377694A (zh) | 2021-03-24 | 2024-01-09 | 詹森生物科技公司 | 包含cd3抗原结合结构域的蛋白质及其用途 |
BR112023019484A2 (pt) | 2021-03-24 | 2023-12-05 | Janssen Biotech Inc | Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3 |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US6018030A (en) * | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
AU638762B2 (en) | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0600866T3 (da) | 1990-06-01 | 1998-03-09 | Chiron Corp | Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
CA2104698A1 (en) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptamers specific for biomolecules and methods of making |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
ATE359842T1 (de) | 1991-07-02 | 2007-05-15 | Nektar Therapeutics | Abgabevorrichtung für nebelförmige medikamente |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
ATE174804T1 (de) | 1992-10-19 | 1999-01-15 | Dura Pharma Inc | Trockenpulverinhalator |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
DK0680451T3 (da) | 1993-01-19 | 1999-07-19 | Glaxo Group Ltd | Aerosoldispenser samt fremgangsmåde ved dens fremstilling |
DE69434437T2 (de) * | 1993-02-05 | 2006-04-06 | Smithkline Beecham P.L.C., Brentford | Fibronektinbindungsprotein, monoklonaler antikoerper und ihre verwendung zur verhuetung der adhäsion von bakterien |
CA2155728C (en) | 1993-02-12 | 2000-04-25 | Gerald R. Crabtree | Regulated transcription of targeted genes and other biological events |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
GB9524630D0 (en) * | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
EA001016B1 (ru) | 1996-01-03 | 2000-08-28 | Глаксо Груп Лимитед | Ингаляционное устройство |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
JP3614866B2 (ja) * | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
EP1015576B1 (en) | 1997-09-16 | 2005-05-04 | Egea Biosciences, LLC | Method for the complete chemical synthesis and assembly of genes and genomes |
AU757153B2 (en) | 1997-09-29 | 2003-02-06 | Novartis Ag | Stabilized preparations for use in metered dose inhalers |
US6846655B1 (en) * | 1998-06-29 | 2005-01-25 | Phylos, Inc. | Methods for generating highly diverse libraries |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
WO2000034784A1 (en) | 1998-12-10 | 2000-06-15 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) * | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
ES2564161T3 (es) * | 2000-07-11 | 2016-03-18 | Research Corporation Technologies, Inc | Polipéptidos de anticuerpos artificiales |
AU2002213251B2 (en) * | 2000-10-16 | 2007-06-14 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
GB0119476D0 (en) * | 2001-08-09 | 2001-10-03 | Novartis Forschungsstiftlung Z | Anti-tumour agents and method of identifying anti-tumour agents |
AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
DE60335000D1 (de) | 2002-09-06 | 2010-12-30 | Isogenica Ltd | In vitro peptid-expressionsbank |
WO2004029224A2 (en) | 2002-09-30 | 2004-04-08 | Compound Therapeutics, Inc. | Methods of engineering spatially conserved motifs in polypeptides |
AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
WO2005056754A2 (en) | 2003-11-19 | 2005-06-23 | The Scripps Research Institute | Compositions and methods to reduce mutagenesis |
US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
CN1946417A (zh) * | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
US20060040278A1 (en) * | 2004-01-27 | 2006-02-23 | Cojocaru Gad S | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer |
SG134283A1 (en) * | 2006-01-24 | 2007-08-29 | Ind Tech Res Inst | Biomarkers for liver fibrotic injury |
JP2009523459A (ja) | 2006-01-24 | 2009-06-25 | ドマンティス リミテッド | 天然の連結部を含有する融合タンパク質 |
WO2008079973A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Egfr binding peptides and uses thereof |
US20110009323A1 (en) | 2007-06-15 | 2011-01-13 | Vasgene Therapeutics, Inc. | Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth |
US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
WO2009058379A2 (en) | 2007-10-31 | 2009-05-07 | Medimmune, Llc | Protein scaffolds |
WO2009086116A2 (en) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Alternative scaffold protein fusions phage display via fusion to plx of m13 phage |
ES2620285T3 (es) | 2008-05-02 | 2017-06-28 | Novartis Ag | Moléculas de unión con base en fibronectina mejorada y usos de las mismas |
AU2009308935B2 (en) | 2008-10-31 | 2015-02-26 | Janssen Biotech, Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
US8415291B2 (en) * | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
EP2452165A1 (en) | 2009-07-07 | 2012-05-16 | Siemens AG | Apparatus and method for measuring multi-phase fluid flow |
EP3569256B1 (en) | 2010-04-30 | 2022-06-15 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
EP2598529A2 (en) | 2010-07-30 | 2013-06-05 | Novartis AG | Fibronectin cradle molecules and libraries thereof |
-
2009
- 2009-10-27 AU AU2009308935A patent/AU2009308935B2/en active Active
- 2009-10-27 JP JP2011534677A patent/JP5848607B2/ja active Active
- 2009-10-27 SI SI200931499A patent/SI2356269T1/sl unknown
- 2009-10-27 CA CA2741834A patent/CA2741834C/en active Active
- 2009-10-27 EP EP09824067.4A patent/EP2356269B1/en active Active
- 2009-10-27 US US12/606,382 patent/US8278419B2/en active Active
- 2009-10-27 RS RS20160813A patent/RS55218B1/sr unknown
- 2009-10-27 DK DK09824067.4T patent/DK2356269T3/en active
- 2009-10-27 PT PT98240674T patent/PT2356269T/pt unknown
- 2009-10-27 EP EP16176749.6A patent/EP3128048B1/en active Active
- 2009-10-27 CA CA3149920A patent/CA3149920A1/en active Pending
- 2009-10-27 LT LTEP09824067.4T patent/LT2356269T/lt unknown
- 2009-10-27 BR BRPI0919881-4A patent/BRPI0919881B1/pt active IP Right Grant
- 2009-10-27 MX MX2011004550A patent/MX2011004550A/es active IP Right Grant
- 2009-10-27 ES ES09824067.4T patent/ES2595504T3/es active Active
- 2009-10-27 CN CN200980153649.4A patent/CN102307896B/zh active Active
- 2009-10-27 PL PL09824067.4T patent/PL2356269T3/pl unknown
- 2009-10-27 WO PCT/US2009/062200 patent/WO2010051274A2/en active Application Filing
- 2009-10-27 ES ES16176749T patent/ES2705714T3/es active Active
- 2009-10-27 KR KR1020117012129A patent/KR101781907B1/ko active IP Right Grant
- 2009-10-27 HU HUE09824067A patent/HUE030471T2/en unknown
- 2009-10-27 EA EA201170635A patent/EA028304B1/ru not_active IP Right Cessation
-
2011
- 2011-04-28 IL IL212531A patent/IL212531A/en active IP Right Grant
-
2012
- 2012-08-27 US US13/595,484 patent/US9200059B2/en active Active
-
2014
- 2014-04-13 IL IL232095A patent/IL232095A/en active IP Right Grant
- 2014-04-13 IL IL232093A patent/IL232093A0/en unknown
- 2014-04-13 IL IL232094A patent/IL232094A/en active IP Right Grant
-
2015
- 2015-05-26 AU AU2015202864A patent/AU2015202864A1/en not_active Abandoned
- 2015-06-03 JP JP2015113064A patent/JP6124267B2/ja active Active
- 2015-10-23 US US14/921,589 patent/US10040842B2/en active Active
-
2016
- 2016-09-09 SM SM201600312T patent/SMT201600312B/it unknown
- 2016-09-28 CY CY20161100961T patent/CY1118120T1/el unknown
- 2016-09-29 HR HRP20161251TT patent/HRP20161251T1/hr unknown
-
2017
- 2017-03-28 JP JP2017062264A patent/JP6599394B2/ja active Active
- 2017-09-29 AU AU2017236012A patent/AU2017236012A1/en not_active Abandoned
-
2018
- 2018-07-11 US US16/032,691 patent/US10654913B2/en active Active
-
2020
- 2020-04-28 US US16/860,613 patent/US11479880B2/en active Active
-
2022
- 2022-09-14 US US17/932,117 patent/US20230071749A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161251T1 (hr) | Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe | |
HRP20161117T1 (hr) | Stabilizirani sastavi fibronektin domena, metode i upotrebe | |
HRP20140982T1 (hr) | Ljudska anti-il-23 antitijela, pripravci, postupci i upotrebe | |
ES2672368T3 (es) | Proteínas agonistas del receptor de TRAIL de cadena sencilla | |
RU2011137464A (ru) | Композиция, способы получения и применение каркаса на основе домена фибронектина типа iii | |
KR101572286B1 (ko) | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 | |
Hymowitz et al. | IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding | |
HRP20150740T1 (hr) | Anti-il-6 antitijela, sastavi, postupci i upotrebe | |
CA2609349A1 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
US20110144014A1 (en) | Cytokine receptor modulators and uses thereof | |
Murray et al. | Pharmaceutical optimization of peptide toxins for ion channel targets: potent, selective, and long-lived antagonists of Kv1. 3 | |
CA2607113C (en) | Interleukin-1 receptor antagonists, compositions, and methods of treatment | |
JP6832887B2 (ja) | 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用 | |
RU2007134566A (ru) | Полипептиды апротинина для транспорта соединения через гематоэнцефалический барьер | |
US20200123223A1 (en) | Single-chain gitr-receptor agonist proteins | |
US11274130B2 (en) | HV1 modulators and uses | |
Dutertre et al. | Determination of α‐conotoxin binding modes on neuronal nicotinic acetylcholine receptors | |
KR20160052537A (ko) | 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 | |
Kim et al. | A microfluidic platform for simulating stem cell migration using in vivo-like gradients of stem cell mobilizer | |
PREUSCH | Equilibrative and concentrative transport mechanisms | |
JP2017526379A (ja) | シャガシンに基づく足場組成物、方法及び使用 | |
NZ725476B2 (en) | Single-chain trail-receptor agonist proteins |